LETTERS

Nova T® 380 and levonorgestrel IUS studies

Madam,

The UK Family Planning and Reproductive Health Care Network have recently completed 5 year studies on these two devices, and following Dr Bacon’s letter we thought it may be useful to give the 24 month results of these studies (Table 1), which have now been published elsewhere.

Table 1 Cumulative life-table gross closure rates at 24 months

<table>
<thead>
<tr>
<th>Nova T 380 Levonorgestrel IUS</th>
<th>N</th>
<th>Pregnancy</th>
<th>Exclusions</th>
<th>Removal for bleeding problems</th>
<th>Pelvic inflammatory disease</th>
<th>Removal to plan</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>572</td>
<td>592</td>
<td>1.9</td>
<td>9.1</td>
<td>17.8</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1.1</td>
<td>5.3</td>
<td>11.9</td>
<td>1.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8.3</td>
</tr>
</tbody>
</table>

In the Nova T® 380 study there were seven pregnancies, of which one had a normal delivery. Three were terminated, one had a spontaneous abortion, and two were ectopic. In the levonorgestrel IUS study there were five pregnancies, of which one had a normal delivery, two had a spontaneous abortion, one was a missed abortion and one was ectopic.

It is our intention to publish the 5 year results during 2001.

Sue Richardson, Chair; Michael Cox, Lead Investigator

Institute of Population Studies, School of Postgraduate Medicine and Health Sciences, University of Exeter, 101 Pennsylvania Road, Exeter EX4 6DT, UK.

References

What indeed is so bad about teenage pregnancy?

Madam,

First we have to ask what is meant by the term ‘teenage pregnancy’ and, indeed, what statistics are gathered regarding teenage pregnancy.

The papers reviewed in this article seem to show adverse outcomes mainly below 16 years of age.

If the term ‘teenage pregnancy’ includes planned pregnancy in 17-19 year old mothers in stable relationships, then many of these are not a major social and medical problem. If the term is restricted to unplanned pregnancies in the teenage years or only pregnancies under the age of 16 years, then I agree that many of these do reflect a major social and medical problem.

I believe more clarity is needed about what exactly the term ‘teenage pregnancy’ really means. If nationally we are collecting statistics that record both high and low risk groups, then they are of very little use in planning local services or allocating resources.

K Leeper, MB ChB, MRCP, FRCOG, DFFP,

Billinghay Medical Practice, 39 High Street, Billinghay, Lincoln, LN4 4AU

Reference

Madam, I read with interest the article ‘What’s so bad about teenage pregnancy’ with interest. I have recently completed a review of 267 teenage pregnancies in the York area from 1995 to 2000. Interestingly it was found that there was no increase in the proportion of premature deliveries and that the average birth weight was almost identical to that of the babies of the non-teens. There was no increase in maternal admission rate or morbidity.

There were two significant findings. Firstly, the incidence of foetal anomaly was three times higher than normal. This has never been described in another study. There was also found to be an incredibly poor recording of contraception in the antenatal care notes and little mention of discussion of any plans for contraception in the future.

Our overall feeling was that the pregnancies were managed well and that few complications arose. This may be due to the relative affluence of the population of York. But the prevention of teenage pregnancy was poor.

Peter Williams, MB BS, DFFP, CoCCLAM

GP Registrar, Postgraduate Medical Centre, York District Hospital, York, UK

Reference

Pre-menarchal prescription of Dianne

Madam,

Standard recommendation is that the combined pill should not be started until after the menarche, since there is a lack of evidence as to the effect an earlier start might have on the pituitary-ovarian axis.

I have just seen a 16-year-old girl in the family planning clinic who reported that she was started on Dianeette at age 12, before her menarche, because of a spotty face. She continued taking it until she was 14.5 years old, and stopped when she changed to tetracycline therapy. She reports no delay in the continuation of regular menses, although they were heavier, without period pain. She attended our clinic at age 15 years and 10 months, weight 50 kg, and was started on the combined pill.

I report this to show that, for one young woman of normal weight, menarche proceeded apparently normally despite therapeutic suppression of ovulation.

Rosemary Kirkman, FRCPG, MFFP

Senior Lecturer in Family Planning and Well Woman Care, Department of Obstetrics and Gynaecology and Reproductive Health Care, Palatine Centre, The University of Manchester, 63-65 Palatine Road, Withington, Manchester, M20 3LI.

Which intra-uterine device should we favour?

Madam,

In common with other family planning doctors with their clients’ best interests at heart, I am keen to make an intelligent and informed decision as to which IUDs are reasonable and efficient alternatives to the Gyne T 380 which we believed to have a superior failure rate compared to the other available copper devices. I was therefore interested to read the report on the Nova T 380 from the UK Family Planning Research Network in the July 2000 issue, which gave a favourably low failure rate of 0-8 per 100 woman-years at 1 year. The report also quoted seven other studies to provide comparisons between the failure rates of the Nova T(200), Nova T 380 and the Gyne T 380 IUD, which might help to compare the devices with regard to failure rate.

However, on close study of these papers and a Medline literature search on other IUDs I have come to the conclusion that far from the published data allowing us to ‘rank’ the available devices, they generally show us no statistically significant differences in the failure rates. A serious omission from the tables in this paper (and others in our Journal) are the probability levels that the results quoted achieve statistical significance. In fact these, and many other studies on IUDs, were on sample sizes of 200-1116 women with event rates (i.e. unintended pregnancy) of 0 to 18, with wide variation between different studies of identical devices. For instance, one study of the much maligned Nova T 200 had the lowest failure rate of all the quoted studies with no failures in the first year (in a sample size of 438 women), which was from our own UK Family Planning Research Network study published in 1989.

As recently as 1995 Farr et al reported a comparative study of the Copper T 380A and the Lippes Loop, giving a failure rate of 2.1 for the Lippes Loop and a potentially impressively low rate for the Copper T 380A of 0.7, but with with little mention in the discharge notes of any plans for contraception in the future.

In common with other family planning doctors I have mentioned, I think it is time we look a long hard look at the statistics on which we base our views of the efficacy of the IUDs. We should probably consider that sample sizes for the modern devices which are all relatively effective will need to be much larger (possibly tenfold) if we want to use these studies to look at fine differences in failure rate.

In the meantime the most scientific approach to choosing a device from the stock cupboard is to consider the effect an earlier start might have on the pituitary-ovarian axis.

Karen Trevinnard, BM MFFP

Instructing Doctor in Family Planning, The Kess to Health, Contraception and Sexual Health Services, 27 Harbour Parade, Southampton, SO15 1BA, UK.

References

Letters to the Editor are welcome and should not normally be longer than 400 words or have more than five references and type should be double spaced. Except in exceptional circumstances, correspondence should be received within 4 weeks of despatch of the most recent Journal. Correspondents should state their qualifications and address.